Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

European label change for Cialis to include 36-hour efficacy claim

Feb. 27, 2004

West Pharmaceutical and Pharmalink to develop IgA-nephropathy treatment

Feb. 26, 2004

Rockwell receives grant for proprietary dialysate iron therapy study

Feb. 25, 2004

DA-8159 effective for inducing erection in rabbit models of spinal cord injury

Feb. 16, 2004

New beta3-adrenoceptor agonists and their use in urinary incontinence

Feb. 13, 2004

Yamanouchi presents new inhibitors of reverse Na+/Ca2+ exchange

Feb. 12, 2004

Comparable results in phase II head-to-head study of TA-1790 and Viagra

Feb. 11, 2004

New PDE5 inhibitors claimed by Janssen scientists

Feb. 9, 2004

European submission for YM-617 TOCAS

Feb. 4, 2004

NDA submission for YM-087 for hyponatremia

Feb. 4, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...